For the first time, we have made it into the Top 10 of PatientView’s ranking of pharmaceutical company reputation among patient organizations. A further improvement in line with previous years, rewarding our ever-increasing commitment to patients and the organizations that represent them.
Overall ranking: Significant improvement
We are honored and proud to be recognized among the top ten companies in the PatientView survey on the reputation of pharmaceutical companies across all therapeutic areas. For the first time, we have reached the 8th spot among patient organizations that work with us, moving up three positions. Among the patient organizations familiar with the Servier Group, we ranked 9th, climbing ten places since last year.
This makes us one of the “fastest risers” in our category!
“This outcome demonstrates the strength of our collective and the collaborations between our different professions. It also underlines our relentless efforts to put patients at the heart of our work, at the heart of our mission.”
Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs, Servier
“Beyond our ranking, which is one indicator, this survey shows that our group-wide strategic approach to patient engagement continues to have a positive impact. Let’s be grateful to the patient communities who pay tribute to our work through this survey.”
Nicolas Garnier, Chief Patient Officer
8th /45
among patient organizations working with the Servier Group
9th /46
among patient organizations familiar with the Servier Group
“Fastest riser”
(selected from among the companies rising the most in the upper rankings)
Source: PatientView’s corporate reputation of pharma, 2024/25. The patient perspective —Global edition
One among many initiatives, the Patient Advisory Councils that we have established bring together people from all continents with the aim of incorporating their opinions and suggestions into our decision-making processes.